BVS Key Statistics, Chart & Performance
The current stock price of BVS is 7.18 USD. In the past month the price decreased by -1.59%. In the past year, price decreased by -28.74%.
BVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.64 | 16.13B | ||
| SOLV | SOLVENTUM CORP | 13.27 | 13.68B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.1 | 11.17B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.34 | 5.15B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.23 | 4.44B | ||
| HAE | HAEMONETICS CORP/MASS | 16.55 | 3.72B | ||
| ICUI | ICU MEDICAL INC | 17.58 | 3.45B | ||
| XRAY | DENTSPLY SIRONA INC | 7.19 | 2.27B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.8 | 1.72B | ||
| NEOG | NEOGEN CORP | 23.38 | 1.52B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.16B | ||
| EMBC | EMBECTA CORP | 3.95 | 686.91M |
Related stock screener links
About BVS
Company Profile
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 950 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Company Info
BIOVENTUS INC - A
4721 Emperor Boulevard, Suite 100
Durham NORTH CAROLINA 27703 US
CEO: Kenneth M. Reali
Employees: 950
Phone: 19194746700
BIOVENTUS INC - A / BVS FAQ
Can you describe the business of BIOVENTUS INC - A?
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 950 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
What is the current price of BVS stock?
The current stock price of BVS is 7.18 USD. The price decreased by -3.49% in the last trading session.
What is the dividend status of BIOVENTUS INC - A?
BVS does not pay a dividend.
What is the ChartMill rating of BIOVENTUS INC - A stock?
BVS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists BVS stock?
BVS stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for BVS stock?
The PE ratio for BIOVENTUS INC - A (BVS) is 12.17. This is based on the reported non-GAAP earnings per share of 0.59 and the current share price of 7.18 USD.
What is the ownership structure of BIOVENTUS INC - A (BVS)?
You can find the ownership structure of BIOVENTUS INC - A (BVS) on the Ownership tab.
BVS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BVS. When comparing the yearly performance of all stocks, BVS is a bad performer in the overall market: 76.93% of all stocks are doing better.
BVS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BVS. BVS has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BVS Financial Highlights
Over the last trailing twelve months BVS reported a non-GAAP Earnings per Share(EPS) of 0.59. The EPS increased by 51.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.39% | ||
| ROA | 1.11% | ||
| ROE | 4.71% | ||
| Debt/Equity | 1.93 |
BVS Forecast & Estimates
7 analysts have analysed BVS and the average price target is 15.3 USD. This implies a price increase of 113.09% is expected in the next year compared to the current price of 7.18.
For the next year, analysts expect an EPS growth of 41.83% and a revenue growth 0.33% for BVS